Monomethyl fumarate augments NK cell lysis of tumor cells through degranulation and the upregulation of NKp46 and CD107a

Hydroxycarboxylic acid receptor 2 mediates dimethyl fumarate’s protective effect in EAE

(2014) Hui Chen et al.   JOURNAL OF CLINICAL INVESTIGATION

Regulation of Ligands for the NKG2D Activating Receptor

(2013) David H. Raulet et al.   Annual Review of Immunology

Detection of fumarate–glutathione adducts in the portal vein blood of rats: evidence for rapid dimethylfumarate metabolism

(2013) Stefan Dibbert et al.   ARCHIVES OF DERMATOLOGICAL RESEARCH

Surface CD107a/LAMP-1 protects natural killer cells from degranulation-associated damage

(2013) A. Cohnen et al.   BLOOD

NK cell-based immunotherapy for malignant diseases

(2013) Min Cheng et al.   Cellular & Molecular Immunology

A One Year Follow-Up Study of Natural Killer and Dendritic Cells Activities in Multiple Sclerosis Patients Receiving Glatiramer Acetate (GA)

(2013) Rune A. Høglund et al.   PLoS One

Role of NK Cell Subsets in Organ-Specific Murine Melanoma Metastasis

(2013) Zuhair K. Ballas et al.   PLoS One

Effects of Vitamin D3, Calcipotriol and FTY720 on the Expression of Surface Molecules and Cytolytic Activities of Human Natural Killer Cells and Dendritic Cells

(2013) Zaidoon Al-Jaderi et al.   Toxins

Natural Cytotoxicity Receptors: Broader Expression Patterns and Functions in Innate and Adaptive Immune Cells

(2013) Kelly Hudspeth et al.   Frontiers in Immunology

Mechanisms of Oxidative Damage in Multiple Sclerosis and Neurodegenerative Diseases: Therapeutic Modulation via Fumaric Acid Esters

(2012) De-Hyung Lee et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Dimethyl Fumarate Inhibits Dendritic Cell Maturation via Nuclear Factor κB (NF-κB) and Extracellular Signal-regulated Kinase 1 and 2 (ERK1/2) and Mitogen Stress-activated Kinase 1 (MSK1) Signaling

(2012) Haiyan Peng et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Recognition and Prevention of Tumor Metastasis by the NK Receptor NKp46/NCR1

(2012) A. Glasner et al.   JOURNAL OF IMMUNOLOGY

NK cells impede glioblastoma virotherapy through NKp30 and NKp46 natural cytotoxicity receptors

(2012) Christopher A Alvarez-Breckenridge et al.   NATURE MEDICINE

Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis

(2012) Robert J. Fox et al.   NEW ENGLAND JOURNAL OF MEDICINE

Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis

(2012) Ralf Gold et al.   NEW ENGLAND JOURNAL OF MEDICINE

Fumaric acid and its esters: An emerging treatment for multiple sclerosis with antioxidative mechanism of action

(2011) R. Gold et al.   CLINICAL IMMUNOLOGY

Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells

(2011) Kamran Ghoreschi et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Regulation of human NK-cell cytokine and chemokine production by target cell recognition

(2009) C. Fauriat et al.   BLOOD

FTY720 and SEW2871 reverse the inhibitory effect of S1P on natural killer cell mediated lysis of K562 tumor cells and dendritic cells but not on cytokine release

(2009) Johannes Rolin et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Enhanced In Vivo Growth of Lymphoma Tumors in the Absence of the NK-Activating Receptor NKp46/NCR1

(2009) G. G. Halfteck et al.   JOURNAL OF IMMUNOLOGY

Combination of Dacarbazine and Dimethylfumarate Efficiently Reduces Melanoma Lymph Node Metastasis

(2009) Teresa Valero et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

The psoriasis drug monomethylfumarate is a potent nicotinic acid receptor agonist

(2008) Hua Tang et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Fumarates for the treatment of multiple sclerosis: potential mechanisms of action and clinical studies

(2008) Ralf A Linker et al.   Expert Review of Neurotherapeutics

Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study

(2008) Ludwig Kappos et al.   LANCET